• Explore /
  • Poster
  • / Dose escalation results of a phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in patients (Pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML).

Dose escalation results of a phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in patients (Pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML).

Abstract Poster

Authors

Harry Erba

Harry Paul Erba

University of Alabama at Birmingham, Birmingham, AL

Harry Paul Erba , Pamela S. Becker , Paul J. Shami , Michael Richard Grunwald , Donna L. Flesher , Yilong Zhang , Erik Rasmussen , Haby A. Henary , Eunice S. Wang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT02016729

Citation

J Clin Oncol 35, 2017 (suppl; abstr 7027)

DOI

10.1200/JCO.2017.35.15_suppl.7027

Abstract #

7027

Poster Bd #

227

Abstract Disclosures

Similar Posters

First Author: Takafumi Koyama

First Author: Xing Zhang

First Author: Anna Spreafico

First Author: Lillian L. Siu